| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ACSM3 |
| Uniprot No | Q53FZ2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-586aa |
| 氨基酸序列 | LHK DNRTATPQNF SNYESMKQDF KLGIPEYFNF AKDVLDQWTD KEKAGKKPSN PAFWWINRNG EEMRWSFEEL GSLSRKFANI LSEACSLQRG DRVILILPRV PEWWLANVAC LRTGTVLIPG TTQLTQKDIL YRLQSSKANC IITNDVLAPA VDAVASKCEN LHSKLIVSEN SREGWGNLKE LMKHASDSHT CVKTKHNEIM AIFFTSGTSG YPKMTAHTHS SFGLGLSVNG RFWLDLTPSD VMWNTSDTGW AKSAWSSVFS PWIQGACVFT HHLPRFEPTS ILQTLSKYPI TVFCSAPTVY RMLVQNDITS YKFKSLKHCV SAGEPITPDV TEKWRNKTGL DIYEGYGQTE TVLICGNFKG MKIKPGSMGK PSPAFDVKIV DVNGNVLPPG QEGDIGIQVL PNRPFGLFTH YVDNPSKTAS TLRGNFYITG DRGYMDKDGY FWFVARADDV ILSSGYRIGP FEVENALNEH PSVAESAVVS SPDPIRGEVV KAFVVLNPDY KSHDQEQLIK EIQEHVKKTT APYKYPRKVE FIQELPKTIS GKTKRNELRK KEWKTI |
| 预测分子量 | 66 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ACSM3重组蛋白的3篇参考文献的简要概括(文献信息为模拟示例，供参考)：
---
1. **文献名称**：*"Recombinant expression and functional characterization of human ACSM3 in lipid metabolism"*
**作者**：Zhang Y, et al. (2020)
**摘要**：研究成功在大肠杆菌中表达并纯化了重组人源ACSM3蛋白，证实其可激活中链脂肪酸(如己酸和辛酸)，并发现其活性受细胞能量状态调控，提示其在脂肪酸氧化代谢中的关键作用。
2. **文献名称**：*"Structural insights into ACSM3 catalysis through recombinant protein crystallography"*
**作者**：Johnson R, et al. (2019)
**摘要**：通过重组ACSM3蛋白的晶体结构解析，揭示了其底物结合口袋的关键氨基酸残基，阐明了该酶催化中链脂肪酸-CoA合成的分子机制，为靶向药物设计提供结构基础。
3. **文献名称**：*"ACSM3 deficiency alters hepatic lipid profiles: Evidence from recombinant protein-based assays"*
**作者**：Lee S, et al. (2021)
**摘要**：利用重组ACSM3蛋白进行体外酶活实验，结合小鼠模型发现，ACSM3表达下调会导致肝脏中链脂肪酸代谢紊乱，可能与非酒精性脂肪肝的发生相关。
---
**备注**：若需实际文献，建议通过PubMed或Web of Science以“ACSM3 recombinant”或“ACSM3 acyl-CoA synthetase”为关键词检索最新研究。
ACSM3 (Acyl-CoA Synthetase Medium-Chain Family Member 3) is an enzyme encoded by the *ACSM3* gene, part of the acyl-CoA synthetase family involved in fatty acid metabolism. It catalyzes the activation of medium-chain fatty acids (typically 4–12 carbons) by binding coenzyme A (CoA) in an ATP-dependent process, forming acyl-CoA thioesters. These products are critical for cellular energy production, lipid biosynthesis, and metabolic signaling pathways. ACSM3 is primarily expressed in tissues with high metabolic activity, such as the liver, kidney, and intestines, where it regulates fatty acid oxidation and maintains lipid homeostasis.
Structurally, ACSM3 contains conserved domains characteristic of the ACS family, including an ATP/AMP-binding motif and a substrate-binding pocket that confers specificity for medium-chain fatty acids. Dysregulation of ACSM3 has been implicated in metabolic disorders, including obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD), due to its role in balancing lipid storage and utilization. Recent studies also suggest potential links to cancer progression, as altered fatty acid metabolism is a hallmark of tumor microenvironment adaptation.
Recombinant ACSM3 protein is produced via heterologous expression systems (e.g., *E. coli* or mammalian cells) for functional and structural studies. Its purified form enables research into enzyme kinetics, substrate specificity, and inhibitor screening, aiding drug development for metabolic diseases. Additionally, recombinant ACSM3 serves as a tool to investigate tissue-specific lipid handling and gene regulation mechanisms. Despite progress, questions remain about its post-translational modifications, interaction partners, and tissue-specific isoforms, highlighting the need for further exploration. Advances in recombinant protein technology continue to enhance the study of ACSM3’s physiological and pathological roles, positioning it as a potential therapeutic target or biomarker for metabolic syndromes.
×
